title: [Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].
abstract: We evaluated the significance of indoleamine 2, 3-dioxygenase (IDO) in breast cancer patients during chemotherapy or trastuzumab therapy. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn were measured by high-performance liquid chromatography(HPLC). The correlations between the Trp/Kyn ratios in the chemotherapy group and the trastuzumab therapy group with respect to pre-chemotherapies or post-chemotherapies were studied. The Trp/Kyn ratio of the chemotherapy group in the post-epirubicin and cyclophosphamide(EC) chemotherapy phase and in the post-weekly paclitaxel(wPTX) chemotherapy phase was lower than that in the pre-chemotherapy phase. In addition, the Trp/Kyn ratio in the chemotherapy group was significantly lower than that in the hormone therapy group in the post-EC chemotherapy phase and in the post-wPTX chemotherapy phase. There were no significant changes in the Trp/Kyn ratio in the trastuzumab therapy group in each phase. These results suggest that trastuzumab therapy may be less invasive than chemotherapy for breast cancer patients.
authors.affiliation: Dept. of Surgery, Nihon University School of Medicine, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakurai
authors.forename: Shigeru
authors.initials: S
authors.lastname: Fujisaki
authors.forename: Saki
authors.initials: S
authors.lastname: Nagashima
authors.forename: Tetsuyo
authors.initials: T
authors.lastname: Maeda
authors.forename: Masahiko
authors.initials: M
authors.lastname: Shibata
authors.forename: Kenshi
authors.initials: K
authors.lastname: Gonda
authors.forename: Ryouichi
authors.initials: R
authors.lastname: Tomita
authors.forename: Shuhei
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Hara
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Enomoto
authors.forename: Sadao
authors.initials: S
authors.lastname: Amano
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000378:metabolism*; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D017239:Paclitaxel / Q000627:therapeutic use*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D003520:Cyclophosphamide; D000068878:Trastuzumab; D017239:Paclitaxel